Salivary gland-type cancers: cross-organ demographics of a rare cancer
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-024-02505-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Aika Tanzawa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Carcinoma, Mucoepidermoid, Carcinoma, Adenoid Cystic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ministry of Education, Culture, Sports, Science and Technology in Japan.
Abstract (Originalsprache)
Background
Salivary gland-type cancers (SGTCs) are histologically heterogeneous and can affect organs other than the salivary glands. Some tumors outside the salivary glands are diagnosed on their unique histological characteristics. Comprehensive cross-organ studies on SGTCs are limited.
Methods
We retrospectively analyzed the data of patients with salivary duct carcinoma (SDC), adenoid cystic carcinoma (AdCC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), acinic cell carcinoma (AcCC), and polymorphous adenocarcinoma (PAC) who visited our institution between 2009 and 2019. The primary tumor sites were classified into four categories; major salivary glands, head/neck (H/N) excluding (exc) major salivary glands (MSG) regions, broncho-pulmonary regions, and “others”. H/N exc MSG was further divided into three subcategories, nasal/paranasal sinus, oral and pharynx/larynx.
Results
We identified 173 patients with SGTCs, with SDC, AdCC, MEC, EMC, AcCC, and PAC accounting for 20%, 42%, 27%, 3%, 8%, and 1% of the cases, respectively. The most frequent primary site was the major salivary glands (64%), followed by H/N exc MSG regions (27%), broncho-pulmonary regions, and “others”, thus non-salivary gland origins accounted for 9% of all cases. Patients with SDC, MEC, AcCC, or SGTC of the major salivary glands and broncho-pulmonary regions were more frequently treated by surgery. The overall survival time of the patients with MEC was significantly better than that of patients with SDC or EMC.
Conclusions
This cross-organ study highlights the clinical significance of SGTCs, underscoring the need for developing novel therapies for this rare disease entity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan.
- Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Molecular Virology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Diagnostic Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Otorhinolaryngology/Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan. takiguchi@faculty.chiba-u.jp.
Förderung
- the Ministry of Education, Culture, Sports, Science and Technology in Japan
Zitieren
APA
Tanzawa, A., Saito, K., Ota, M., Takahashi, K., Ohno, I., Hanazawa, T., Uzawa, K., & Takiguchi, Y. (2024). Salivary gland-type cancers: cross-organ demographics of a rare cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02505-3
Vancouver
Tanzawa A, Saito K, Ota M, Takahashi K, Ohno I, Hanazawa T, et al. Salivary gland-type cancers: cross-organ demographics of a rare cancer. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02505-3
BibTeX
@article{Tanzawa2024,
author = {Tanzawa, Aika and Saito, Kengo and Ota, Masayuki and Takahashi, Koji and Ohno, Izumi and Hanazawa, Toyoyuki and Uzawa, Katsuhiro and Takiguchi, Yuichi},
title = {Salivary gland-type cancers: cross-organ demographics of a rare cancer},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-024-02505-3}
}
EUVIMED